BioCentury
ARTICLE | Clinical News

CAR-T CD30: Phase I data

May 25, 2015 7:00 AM UTC

Data from 7 evaluable patients with relapsed and refractory Hodgkin’s lymphoma in an open-label, Chinese Phase I trial showed that CAR-T CD30 led to an objective response rate (ORR) of 28.6% and a dis...